
· Executive Brief
National Cholesterol Education Month 2026
A practical executive framework for access, ownership, handoffs, measurement, and improvement.

Leadership signal
National Cholesterol Education Month can serve as an executive operating checkpoint.
Awareness can generate questions and requests for help. Executive teams can prepare by clarifying the first point of contact, the qualified team that accepts the request, the handoff standard, and the method used to verify completion without assuming that one route fits every person.
Start by distinguishing what is known from what the organization still needs to learn. A campaign plan, communication volume, or meeting count does not establish that a route is usable. Leaders need direct listening, clear ownership, locally defined measures, and a method for keeping exceptions visible.
Executive opening
Cholesterol control is a follow-through problem
Lowering LDL cholesterol is one of the most established tools in cardiovascular prevention, yet health systems routinely fall short of using it. The gap rarely reflects a lack of effective medicine. It reflects a pathway that depends on testing, prescribing, filling, intensifying and refilling, with a different owner at almost every step. National Cholesterol Education Month is a useful moment for executives to ask where that pathway breaks. The answer is usually found in the spaces between departments, where a result, a referral or a refill depends on someone noticing it.
The gaps are visible even after the highest-risk events. In a cohort of 47,416 adults discharged on lipid-lowering therapy after a myocardial infarction or coronary revascularization, 12% lacked LDL cholesterol testing in the first year.[9] The share without testing rose from 44% in year 2 to 64% in year 10.[9] Monitoring fades just when long-term control matters most. Each untested year is a year in which a rising LDL level can go unnoticed.
Treatment intensity also stalls. In a nationwide study of 4956 adults with type 2 diabetes in Turkey, 99.5% required statin therapy, but only 37.1% were on treatment.[10] Therapeutic inertia, defined as no intensification despite LDL cholesterol above target, was present in 87.2% of patients.[10] Those findings come from outside the United States, but the same failure points exist in any system where follow-up is nobody’s explicit job.
The sections below summarize current peer-reviewed research on burden, detection, adherence, outreach, workforce models, equity and measurement. They sit beside the executive guidance already on this page. They are intended to give boards and operating leaders a shared factual base for choosing which lipid handoff to make reliable first, without offering advice on individual treatment.
Current evidence
What the research says about treatment gaps and adherence
Target attainment remains low across settings and risk groups. In the Turkish diabetes study, only 8.3% of the cohort achieved LDL cholesterol targets, and attainment was lowest among those at very high risk, at 5.8%.[10] Among statin users, target achievement was 57.7% in moderate-risk, 18.1% in high-risk and 9.4% in very high-risk patients.[10] Statin therapy was the strongest positive predictor of success (odds ratio 2.39).[10] Smoking, female sex, older age and higher HbA1c were associated with a lower likelihood of reaching goals.[10] The pattern suggests that the patients with the most risk are often the least well served.
Control after a coronary event is also incomplete. Target LDL cholesterol attainment was 67% in year 1 and 57–60% in years 2–10 in the post-event cohort.[9] There was a clear upward trend over time, from 58% in 2012 to 77% in 2022.[9] Attaining the target predicted 21% and 16% lower risk of subsequent atherosclerotic and composite cardiovascular events, respectively.[9]
Adherence is the next point of loss. Among 9522 privately insured people with HIV who started a statin, 50.0% discontinued within 2 years, and 26.5% had low adherence during therapy.[2] In Czech claims data covering approximately 40% of the insured population, 61.0% of 890,180 prevalent statin users reached a proportion of days covered of at least 80%.[14] In the same prevalent cohort, 83.5% reached a proportion of days covered of at least 50%.[14] The gap between those two thresholds is where many patients sit.
Adherence patterns vary by age and treatment history. In the Czech incident cohort of 287,871 patients, median proportion of days covered among adults aged 18 to 39 rose from 84.1% in the first treatment sequence to 94.7% in the third.[14] Female gender was associated with lower odds of adherence (odds ratio 0.896).[14] Younger patients and those early in therapy may need more deliberate support.[14] The first months after a new prescription are therefore a sensible focus for outreach.
Measurement method can change the picture. A blood test for statin levels among 451 coronary outpatients found that 9% (n = 39) had reduced adherence.[15] Among those classified as adherent by the blood test, 28% (n = 115) had a dispensing gap of at least 90 days at some point during a median 5.9 years of follow-up.[15] Pharmacy data and direct measures each capture a different slice of the adherence problem. Health systems that rely on one source alone may misjudge both the size of the gap and the patients who need help.
Figure 1
Most high-risk patients are not at their LDL cholesterol target
Percent of patients at LDL cholesterol target, as defined in each study. Values are copied from the cited studies [5], [7], [9], [10]; none is estimated.
Data note. These values come from different countries, populations, risk groups and target definitions, so this is an indirect comparison; only the two bars from the same health system compare directly.
Limitation. Targets differ by guideline and risk category, and each study used its own data source and period.
Figure data (5 rows)
| Measure | Value | Population, setting and year as reported | Source |
|---|---|---|---|
| Adults with type 2 diabetes at target | 8.3% | 4956 adults in 70 tertiary endocrine clinics in Turkey, 2022 to 2023 | [10] |
| Adults aged 70 or older on statins at target | 17.8% | 360 adults in primary prevention at a tertiary hospital in Vietnam, 2021 targets | [5] |
| Women with cardiovascular disease below 70 mg/dL | 31% | Large health system, adults with lipid testing in 2022 to 2023 | [7] |
| Men with cardiovascular disease below 70 mg/dL | 47% | Same health system and period | [7] |
| Adults at target in the first year after a coronary event | 67% | 47,416 adults discharged on lipid-lowering therapy, baseline 2012 to 2022 | [9] |

Continuum of care
From first test to sustained control
The lipid pathway begins with how treatment is started. A cohort of 255,730 statin-naive patients started on statins for primary prevention found that 67.7% had a cardiovascular risk score recorded at initiation.[3] The presence of a score was associated with a 7% increase in adherence and an 8% reduction in discontinuations.[3] It was also associated with a 15% reduction in cardiovascular disease and all-cause mortality.[3]
The authors treated a missing risk score as a possible sign that shared decision making had not taken place.[3] They noted that the mortality difference could not be fully explained by better adherence and called for further investigation.[3] For health systems, the operating point is that the quality of the first conversation may shape what happens for years afterward.
Decision tools embedded in the record can support that first conversation. In a Cleveland Clinic cohort of 17,001 statin-naive adults, 13% viewed the Statin Choice tool, and 7% were prescribed a statin.[13] Patients shown the tool had 9.04 higher odds of being prescribed a statin and, once prescribed, 5.75 higher odds of filling it.[13] At 12 months, the association with adherence was not significant after adjustment for patient factors.[13]
The handoff after an acute event is equally important. In the post-event cohort, cardiac rehabilitation participation and adherence to lipid-lowering therapy were associated with improved LDL cholesterol control.[9] That makes discharge planning, rehabilitation referral and the first follow-up test a single chain rather than separate tasks. A missed test in year 2 is a signal that the chain has broken. Because responsibility often shifts from cardiology to primary care after the first year, the handoff between them deserves a named owner and an agreed standard.
Follow-through also depends on intensification. In the Turkish diabetes cohort, the 87.2% rate of therapeutic inertia shows how often a high result was not followed by a change in therapy.[10] A result that is drawn but not acted on adds cost without adding protection. Executives can ask how many above-target results within their system are followed by a documented next step within a defined period. That single measure tests whether testing, review and prescribing are connected. It also shows whether responsibility for acting on a result is clearly assigned or left to chance.
Figure 3
Why the pathway breaks
People
- No named owner for follow-up testing after a coronary event
- Pharmacist capacity not used for lipid management
- Limited time for shared decisions at statin initiation
Process
- Above-target results not followed by intensification
- Single outreach attempt with no follow-up to nonresponders
- No referral route for suspected familial hypercholesterolemia
Technology
- Decision tools available but rarely opened
- Case-finding algorithms not applied to existing records
- Point-of-care devices not validated against laboratory methods
Environment
- Testing requires a separate appointment
- Mental health and specialty services without lipid testing
- Patients lost when moving between hospital and primary care
Policy
- Guideline target changes that shift apparent performance
- Coverage barriers to combination therapy
- No standard for monitoring after acute events
Measurement
- LDL calculation method changes who is flagged
- Adherence measured only by fills
- Results not stratified by sex, race and ethnicity, or age
Unranked qualitative cause-and-effect diagram for the outcome in the box: Patients at high cardiovascular risk do not reach or sustain LDL cholesterol control Causes are assembled from the cited literature [1], [4], [6], [8], [9], [10], [12], [15]; categories are not weighted and their order carries no meaning.
Data note. Qualitative; no frequencies are implied.
Limitation. Causes drawn from published studies may not all apply locally; validate them with frontline teams.
Figure data (6 rows)
| Category | Causes drawn from the cited literature |
|---|---|
| People | No named owner for follow-up testing after a coronary event; Pharmacist capacity not used for lipid management; Limited time for shared decisions at statin initiation |
| Process | Above-target results not followed by intensification; Single outreach attempt with no follow-up to nonresponders; No referral route for suspected familial hypercholesterolemia |
| Technology | Decision tools available but rarely opened; Case-finding algorithms not applied to existing records; Point-of-care devices not validated against laboratory methods |
| Environment | Testing requires a separate appointment; Mental health and specialty services without lipid testing; Patients lost when moving between hospital and primary care |
| Policy | Guideline target changes that shift apparent performance; Coverage barriers to combination therapy; No standard for monitoring after acute events |
| Measurement | LDL calculation method changes who is flagged; Adherence measured only by fills; Results not stratified by sex, race and ethnicity, or age |
Access
Bringing testing and outreach to where patients are
Point-of-care testing can bring lipid checks into services that patients already use. In early intervention in psychosis services across all eight mental health trusts in South East England, 40 testing machines were introduced from March to May 2021.[12] Afterward, lipid testing increased significantly (odds ratio 2.38), as did total completed physical health checks (odds ratio 3.61).[12] These increases were not seen in the comparison region.[12]
Clinicians in that evaluation reported improved patient engagement and patients’ preference for finger-prick testing over traditional blood tests.[12] People with psychosis face a significant mortality gap, and completion of cardiovascular risk checks in this group had been suboptimal.[12] Bringing the test to the encounter removed a separate appointment that many patients would not have attended. Clinician training and support were provided as part of the rollout.[12] The same approach could apply to other services where patients with high cardiovascular risk are seen often but tested rarely, such as substance use treatment or community clinics.
Device accuracy is part of the access decision. A study of 120 participants compared a commercial point-of-care lipid system with the reference laboratory method.[11] Triglycerides showed excellent agreement, while total cholesterol, HDL cholesterol, non-HDL cholesterol and LDL cholesterol showed good agreement (intraclass correlation range 0.817–0.854).[11] Sensitivities ranged from 94.29% to 98.33% and specificities from 68.33% to 91.80%.[11]
The authors concluded that systematic bias limits complete interchangeability with laboratory methods, though the device performed well as a screening tool.[11] For executives, that distinction matters. Point-of-care testing can widen access to screening, but the pathway should define when a laboratory confirmation is needed before treatment decisions. The authors noted the device’s potential value in resource-limited settings.[11] Procurement, training and quality control belong in the same decision as the device itself.
Digital outreach extends access between visits. In a pragmatic trial at Kaiser Permanente Northern California with 20 604 adults with recent statin nonadherence, initial digital outreach increased 14-day statin refill compared with usual communication (14.4% vs 12.0%).[1] Cumulative refill through 28 days was 24.9% with any digital outreach versus 21.2% with usual communication.[1] Results were consistent across prespecified subgroups.[1] The participant population was diverse, including 27.8% Asian, 10.9% Black and 33.6% Hispanic adults.[1] Low-cost digital contact can reach many patients at once, but it works only if refill routes, pharmacy access and coverage are ready to respond.
Executive guidance · System route
Build one visible operating route for National Cholesterol Education Month.
Use this route as a discussion framework. Replace each stage with the organization’s approved process, qualified roles, current service capacity, and applicable requirements. Do not infer a clinical protocol from the observance title.
The route at a glance
- Listen
- Clarify entry
- Connect the recovery route
- Protect transitions
- Verify and learn
Reliability rule: Every stage needs a named owner, an observable status, an approved escalation path, and a defined signal that shows whether responsibility moved or remained unresolved.
Listen
Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions.
Clarify entry
Publish a plain-language first step and identify who receives requests through each approved channel.
Connect the recovery route
Where locally relevant, make transitions among information, evaluation, services, recovery support, and follow-through visible without prescribing a clinical pathway.
Protect transitions
Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations.
Verify and learn
Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals.
Figure 2
The system route as one flow
The five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.
Data note. Shows sequence and handoffs only; it carries no counts or rates.
Limitation. Local processes may add, merge or reorder stages under organizational policy.
Figure data (5 rows)
| Stage | What the stage requires |
|---|---|
| Listen | Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions. |
| Clarify entry | Publish a plain-language first step and identify who receives requests through each approved channel. |
| Connect the recovery route | Where locally relevant, make transitions among information, evaluation, services, recovery support, and follow-through visible without prescribing a clinical pathway. |
| Protect transitions | Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations. |
| Verify and learn | Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals. |
Equity and trust
Treatment gaps are not evenly shared
Sex differences appear at nearly every stage of lipid care. In a chart review of 364,021 adults with lipid testing in a large health system, women had higher mean LDL cholesterol than men (108 vs 102 mg/dL).[7] Among those with atherosclerotic cardiovascular disease, only 31% of women versus 47% of men achieved an LDL cholesterol below 70 mg/dL.[7]
Prescribing showed the same pattern. Women were less likely to be prescribed statins (26% vs 33%) overall and less likely to receive high-intensity statins in the population with cardiovascular disease (23% vs 31%).[7] No prescribing difference was noted between male and female providers across specialties.[7] The authors described this as a systemic gap rather than one driven by provider gender.[7] They suggested provider education, electronic health record reminders and pharmacist-led programs as targeted responses.[7] Each of those is an operating choice that a health system controls.
Adherence gaps follow similar lines. Among people with HIV starting statins, 59.0% of women and 48.1% of men had discontinued within 2 years (adjusted hazard ratio 1.30).[2] Among those remaining on statins, low adherence was more common among women (34.1%) than men (25.2%).[2] People with HIV, particularly women, carry a high cardiovascular burden compared with the general population.[2] The authors called for efforts to address adherence barriers, especially among women with HIV.[2] HIV clinics are therefore a natural site for lipid follow-up, provided their teams have the tools and time to do it.
Age and sex interact. In a cross-sectional study of 360 adults aged 70 or older receiving statins for primary prevention in Vietnam, only 17.8% achieved 2021 guideline-recommended LDL cholesterol targets.[5] Male sex was the strongest predictor of target achievement (adjusted odds ratio 2.64).[5] A 2025 guideline update reclassified 14.2% of participants to lower risk categories, raising apparent achievement to 20.3%, mainly among non-frail adults.[5]
Race and ethnicity also matter. In the post-event cohort, women and African American patients had lower target attainment.[9] Health systems can make these gaps visible by stratifying testing, prescribing, intensification and target attainment by sex, race and ethnicity, and age. A guideline change that improves headline rates can hide unequal progress, so stratified review should continue after any definitional change.[5] Equity review is most useful when it is built into routine dashboards rather than produced once for a special report. Community partners and patient advisers can help explain why gaps persist where data alone cannot.

Human infrastructure
Team models that close the lipid gap
Pharmacists can take on structured lipid management. In a randomized trial of 123 adults with above-target LDL cholesterol, a 4-step pharmacist-led intervention achieved higher goal attainment at 12 months than usual care (45.5% vs 25.9%).[6] Of the randomized participants, 109 (88.6%) completed follow-up.[6] LDL cholesterol fell by 0.67 mmol/L in the intervention group versus 0.08 mmol/L with usual care.[6]
The same trial found that adoption of lipid-lowering drugs at 1 year was 80.0% with the pharmacist model versus 59.3% with usual care.[6] Nonstatin agent adoption was 20.0% versus 3.7% when shared decision-making was used.[6] The authors described the framework as a scalable template for integrating pharmacists into multidisciplinary cardiovascular care.[6] The trial was small and open-label, so local results may differ.[6] Even so, it shows how a defined role with a clear protocol can take ownership of a step that physicians often lack time to complete.
Detection of familial hypercholesterolemia depends on whether teams apply case-finding tools. The condition is diagnosed in fewer than 10% of cases globally.[4] In a clinical cohort of 501 Qatari patients from diabetes and cardiology clinics, the Dutch Lipid Clinic Network criteria classified 12.6% as definite and 21.8% as probable cases.[4] A predictive algorithm identified 35.5% as suspected cases.[4]
The authors estimated that about one in three to four patients in those clinics was a likely case, depending on the criteria used.[4] They concluded that applying case-finding tools in patients with high cholesterol can improve detection.[4] The three tools showed similar classification between sexes.[4] For health systems, that suggests a defined role, often in lipid clinics, cardiology or pharmacy, for reviewing flagged patients and arranging confirmation and family follow-up.
Laboratory and informatics staff are part of the team as well. In 13,834 hospitalized patients, the share at LDL cholesterol goal was 38.9% using the Friedewald equation but 35.8% and 32.6% using two newer equations.[8] Patients with diabetes were reclassified as not at goal more often than those without diabetes.[8] The choice of calculation is a governance decision that affects which patients are flagged for action.[8] Distance to target was also higher with the newer equations, particularly among patients with diabetes.[8] Laboratory leaders, informatics teams and clinical leaders should agree on the method together and communicate any change.
Executive guidance · Operating dashboard
Use a small dashboard to expose friction and ownership.
Do not publish a number until the organization defines its numerator, denominator where relevant, owner, source system, exclusions, review cadence, and limits. The candidates below are management prompts, not benchmarks or reported results.
Four operating signals
Each signal pairs an executive question with one candidate local measure, set out below.
Executive guidance · Signal
Entry-point clarity
Can people and staff identify the approved first step without searching across conflicting instructions?
- Candidate local measure
- Locally defined contact, routing, and repeat-contact signals by channel and service.
Executive guidance · Signal
Ownership reliability
Does a specific team accept each request and make its status visible?
- Candidate local measure
- Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
Executive guidance · Signal
Recovery-route ownership
Where locally applicable, can people and teams identify the next owner across services and recovery support?
- Candidate local measure
- Locally defined transition acceptance, missing information, unresolved routes, repeat contacts, and experience feedback.
Executive guidance · Signal
Improvement closure
Does the organization correct recurring friction and report what changed?
- Candidate local measure
- Selected barriers, assigned actions, completion status, and post-change review.
Figure 4
The operating system behind the dashboard
The four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.
Data note. Structural diagram; no measured values.
Limitation. Owners are candidates to be confirmed locally.
Figure data (4 rows)
| Operating signal | Candidate owner |
|---|---|
| Entry-point clarity | Executive sponsor and operational lead |
| Ownership reliability | Operational owner and participating teams |
| Recovery-route ownership | Sending and receiving owners |
| Improvement closure | Improvement owner and executive sponsor |
Executive guidance · Handoff workflow
Close the loop across teams, settings, and partners.
A handoff is reliable only when the sending party knows who is expected to receive the work, the receiving party acknowledges responsibility, and any unresolved exception remains visible. Local policy and qualified judgment control the actual process.
How responsibility moves
Lane A
From message to accepted ownership
- Confirm the approved message and intended audience.
- Publish the actual entry point and receiving role.
- Acknowledge receipt using the locally approved method.
- Escalate when ownership or response remains unclear.
Lane B
From accepted ownership to verified follow-through
- Record the next accountable owner and visible status.
- Confirm the receiving owner and next contact across services or recovery support where locally applicable.
- Keep unresolved work visible across boundaries.
- Confirm closure or document the continuing exception.
Executive guidance · Executive scorecard
Give leaders one view of route reliability and improvement.
The scorecard keeps review focused on decisions. Leaders should set definitions locally, examine variation without overclaiming cause, and pair quantitative signals with the experience of people who use and operate the route.
Who reviews what
- Executive sponsor and operational lead
- Operational owner and participating teams
- Sending and receiving owners
- Improvement owner and executive sponsor
Candidate owners named in the scorecard, confirmed locally.
| Operating signal | Executive question | Candidate owner | Suggested review point |
|---|---|---|---|
| Entry-point clarity | Can people and staff identify the approved first step without searching across conflicting instructions? | Executive sponsor and operational lead | At campaign launch and close |
| Ownership reliability | Does a specific team accept each request and make its status visible? | Operational owner and participating teams | At a locally defined cadence |
| Recovery-route ownership | Where locally applicable, can people and teams identify the next owner across services and recovery support? | Sending and receiving owners | At a locally defined cadence |
| Improvement closure | Does the organization correct recurring friction and report what changed? | Improvement owner and executive sponsor | Until action is verified |
Figure 5
Control points for a reliable lipid management pathway
| Control point | Risk if missing | Owner | Evidence of control |
|---|---|---|---|
| LDL cholesterol test after a coronary event | Patients lose monitoring in later years | Cardiology and primary care leads | Share of post-event patients with an annual LDL result |
| Action on above-target results | Therapeutic inertia persists | Pharmacy or lipid clinic lead | Documented next step within a defined period |
| Risk discussion at statin initiation | Low adherence and early discontinuation | Primary care medical director | Recorded risk score or decision tool use at initiation |
| Refill outreach with follow-up for nonresponders | Nonadherence goes unaddressed | Population health lead | Refill rates after first and second outreach |
| Familial hypercholesterolemia flag and referral | Cases and relatives remain undiagnosed | Lipid clinic or genetics lead | Flagged patients reviewed and referred |
| Laboratory method governance | Goal status misclassified | Laboratory director | Documented LDL calculation method and change log |
| Equity stratification | Gaps by sex and race remain hidden | Quality and equity leads | Measures reported by sex, race and ethnicity, and age |
Control points derived from the cited evidence [1], [3], [4], [6], [7], [8], [9] and this brief’s executive guidance.
Data note. Each row is a control to verify, not a measured result.
Limitation. Owners and evidence of control must follow local policy and applicable requirements.
Public communication
Outreach, shared decisions and the measures that matter
Communication strategies can be tested like any other intervention. In the Kaiser Permanente trial, participants were randomized to secure portal messaging, text messaging, email or usual communication.[1] Among initial nonresponders, a second outreach further increased refill (13.0% vs 10.4%).[1] Switching to a different communication channel did not improve refill compared with repeating the same one (13.2% vs 12.5%).[1]
Those results point to persistence rather than novelty as the lever in outreach.[1] The trial was embedded in routine operations and rapidly implemented, which shows that health systems can generate their own evidence on outreach design.[1] Population health teams can apply the same approach to lipid testing reminders, intensification visits and refill prompts. Small embedded trials can show which message, timing and sequence work for local patients. That evidence is more persuasive to clinicians than assumptions about what patients prefer.
Shared decision making is a form of communication with measurable effects. In the Cleveland Clinic cohort, patients shown the decision tool had an average 12 mg/dL greater reduction in LDL cholesterol at 12 months than those not shown it.[13] The authors noted that a randomized trial is needed to confirm causality.[13] In the risk-score cohort, the authors called for renewed focus on communicating cardiovascular risk at statin initiation.[3]
Measurement choices shape what leaders see. The Czech study recommended integrating the proportion of days covered into clinical practice to monitor and improve adherence.[14] The coronary blood test study suggested that a single direct measure can complement pharmacy data.[15] The laboratory study showed that the LDL calculation method can change apparent goal attainment by several percentage points.[8]
Boards should therefore ask for a small, stable set of lipid measures with clear definitions. Testing after a cardiovascular event, target attainment by risk group, intensification after an above-target result and refill persistence are candidates. Each should be stratified by sex, race and ethnicity, and age, and reviewed alongside the executive guidance on this page. Public messages during the observance can then point to real services, such as a testing site, a pharmacist visit or a refill line. A campaign that invites people to know their numbers should be matched by a system ready to act on them.

Executive guidance · 90-day plan
Turn the observance into one sustained operating change.
The time boxes below are a management framework, not a clinical timeline. Adjust them to risk, scope, governance, resources, stakeholder participation, and applicable review requirements.
Ninety days, three moves
- Days 1–30See the current route
- Days 31–60Build the reliable path
- Days 61–90Make the change visible
Days 1–30 · Listen and map
See the current route
- Name an executive sponsor and an operational owner.
- Listen to people using the route and representative frontline teams.
- Map how National Cholesterol Education Month communications connect to real entry points, owners, transitions, and escalation.
- Select one recurring barrier that the organization can responsibly address.
Days 31–60 · Design and test
Build the reliable path
- Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
- Validate the design with every sending and receiving team involved.
- Review one locally relevant service-to-recovery handoff and verify that ownership remains visible.
- Test the route in more than one representative setting or operating period where practical.
Days 61–90 · Implement and verify
Make the change visible
- Launch the redesigned route with a small set of locally defined measures.
- Review unresolved work and recurring friction using a learning approach.
- Correct implementation barriers and record who owns each remaining dependency.
- Report what changed, what evidence was reviewed, and what still requires live oversight.
Figure 6
The 90-day plan on one timeline
The 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.
Data note. Time boxes are a management framework, not a clinical timeline.
Limitation. Durations are uniform 30-day windows; real tasks may span windows.
Figure data (12 rows)
| Window | Action |
|---|---|
| Days 1–30 · Listen and map | Name an executive sponsor and an operational owner. |
| Days 1–30 · Listen and map | Listen to people using the route and representative frontline teams. |
| Days 1–30 · Listen and map | Map how National Cholesterol Education Month communications connect to real entry points, owners, transitions, and escalation. |
| Days 1–30 · Listen and map | Select one recurring barrier that the organization can responsibly address. |
| Days 31–60 · Design and test | Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal. |
| Days 31–60 · Design and test | Validate the design with every sending and receiving team involved. |
| Days 31–60 · Design and test | Review one locally relevant service-to-recovery handoff and verify that ownership remains visible. |
| Days 31–60 · Design and test | Test the route in more than one representative setting or operating period where practical. |
| Days 61–90 · Implement and verify | Launch the redesigned route with a small set of locally defined measures. |
| Days 61–90 · Implement and verify | Review unresolved work and recurring friction using a learning approach. |
| Days 61–90 · Implement and verify | Correct implementation barriers and record who owns each remaining dependency. |
| Days 61–90 · Implement and verify | Report what changed, what evidence was reviewed, and what still requires live oversight. |
Executive guidance · Leadership close
Make National Cholesterol Education Month a starting point, not an endpoint.
Recognition matters. It becomes durable when leaders also listen, clarify the route, support the people operating it, close an identified gap, and report the result without claiming more than the evidence supports.
Leadership commitment
Make ownership visible, test the route, and report what improved.
Executive action kit · Month observance
Turn National Cholesterol Education Month into accountable action.
A practical executive framework for access, ownership, handoffs, measurement, and improvement.
Leadership focus
Use this observance to examine navigation, longitudinal ownership, and specialty-care coordination. Select one verified barrier, assign an accountable owner, and carry the improvement beyond the campaign window.
Workforce lens
Ask whether staffing, role clarity, training, tools, workload, and escalation support the people operating the information, acute-to-ambulatory transition, rehabilitation, and follow-through pathway.
Patient and community lens
Make the approved first step clear. Test whether a person can move from information to an acknowledged next action without navigating conflicting instructions.
Equity and access lens
Review transportation, language, digital access, affordability, geography, disability, and whether the recovery route works across different settings.
Five-minute briefing
Inspect the operating sequence
Listen with patients, caregivers, cardiovascular teams, rehabilitation, pharmacy, and ambulatory partners. Find one an unowned transition, unclear recovery route, or unresolved access need, then test the locally approved route from entry through acknowledged follow-through.
- Listen
- Clarify entry
- Connect the recovery route
- Protect transitions
- Verify and learn
Leadership actions for this week
- Name an executive sponsor and frontline operating owner.
- Ask people using and operating the pathway where ownership becomes unclear.
- Test one representative route from first question to acknowledged next step.
- Select one barrier that can be corrected without overstating the evidence.
- Set a review date and define how completion will be verified.
Candidate measures
Define every numerator, denominator where relevant, owner, data source, exclusions, cadence, and limitation locally. These are management prompts, not external benchmarks.
- Locally defined contact, routing, and repeat-contact signals by channel and service.
- Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
- Locally defined transition acceptance, missing information, unresolved routes, repeat contacts, and experience feedback.
Department readiness checklist
- The public and staff entry points match the actual approved process.
- A specific role accepts each request, referral, or escalation.
- Handoffs include acknowledgment and a visible unresolved state.
- Language, disability, digital, transportation, and trust barriers receive explicit review.
- Communications do not introduce unsupported themes, statistics, or clinical advice.
- A named leader will review what changed after the observance.
Intended audiences
- Executive and Operational Leaders
- Patient Experience and Access Leaders
Staff communication template
During National Cholesterol Education Month, our organization will connect awareness with a practical review of the information, acute-to-ambulatory transition, rehabilitation, and follow-through pathway. Use approved information, identify the correct entry point, confirm ownership when work moves, protect privacy, and escalate unresolved barriers through local channels.
Community communication template
National Cholesterol Education Month is an opportunity to share trustworthy information and make the next step easier to find. Use our approved channels for information and support. If a request changes hands, our goal is to keep ownership and follow-through visible.
Measurement worksheet
- Signal
- What observable condition will show whether the route works?
- Definition
- What is included, excluded, and counted?
- Owner
- Who reviews the signal and acts on exceptions?
- Cadence
- When will leaders review it?
- Equity check
- Which differences require protected, locally appropriate review?
- Closure
- What evidence will confirm the improvement was completed?
- Editorial review
- Completed
- Source records
- 2 listed under Authoritative resources
- Review standard
- Sourced facts remain separated from original executive guidance
- Clinical boundary
- No new statistical or clinical claim was added by this action kit
Sources and content boundary
Authoritative resources
Use note: All operating models, measures, scorecard questions, and action steps are original executive guidance. This article supports leadership planning and education. It does not replace clinical judgment, emergency procedures, legal advice, professional standards, organizational policy, or applicable federal, state, and local requirements.
Peer-reviewed references
References
Fifteen peer-reviewed sources, newest first. Each was individually verified through authenticated academic research databases. Bracketed numbers in the text link here; the original executive guidance on this page carries no citations because it is guidance, not a sourced claim. Sources last checked in those databases on .
- 1.Bhatt AS, Liu VX, Sun B, Apostol-Largeteau M, Marafino BJ, Amiri M, et al. Digital Outreach to Improve Statin Refills in Patients With Low Statin Adherence: The ADHERE-ASCVD Randomized Clinical Trial. JAMA. 2026. https://doi.org/10.1001/jama.2026.16372
- 2.Davy-Mendez T, Kinlaw AC, Tungate Lopez S, Okeke NL, Floris-Moore M, Eron JJ, et al. Gender Differences in Statin Discontinuation and Adherence Among Privately Insured People with HIV in the USA. Journal of General Internal Medicine. 2026;41(10):2873-2881. https://doi.org/10.1007/s11606-025-10164-x
- 3.Finnikin S, Willis B, Evans T, Finney B, Hui KNC, Khatib R, et al. Cardiovascular Risk Estimation and Statin Adherence: A Historical Cohort Study. Medical Decision Making. 2026:272989X261455267. https://doi.org/10.1177/0272989x261455267
- 4.Toor SM, Akyea RK, Mohammed S, Al Hail MSH, El-Menyar A, Gomaa M, et al. Improving the clinical diagnosis of familial hypercholesterolemia among patients attending diabetes and cardiology clinics. American Journal of Preventive Cardiology. 2026;27. https://doi.org/10.1016/j.ajpc.2026.101431
- 5.Nguyen HLH, Pham ATN, Tran TT. Sex disparities in LDL-C target achievement among older adults receiving statin therapy. Journal of Geriatric Cardiology. 2026;23(7):435-445. https://doi.org/10.26599/1671-5411.2026.07.002
- 6.Chai DY, Han HY, Xu C, Liu S, Duan H, Wang L. Pharmacist-led standardized intervention framework improves LDL-C goal attainment in lipid-lowering therapy: A randomized controlled trial. Journal of Clinical Lipidology. 2026;20(7):1464-1472. https://doi.org/10.1016/j.jacl.2026.05.008
- 7.Vartak N, Ong C, Huang X, Weintraub S, Parikh N, Rosen S, et al. Gender differences in lipid management, LDL-C goal attainment, and prescribing practices. Journal of Clinical Lipidology. 2026;20(2):438-443. https://doi.org/10.1016/j.jacl.2025.12.008
- 8.Capece U, Iacomini C, Morciano C, Gugliandolo S, Splendore A, Cesario A, et al. Impact of the Friedewald equation vs 2 validated equations on LDL-C estimates and goal achievement in hospitalized patients with diabetes. Journal of Clinical Lipidology. 2026;20(6):1166-1177. https://doi.org/10.1016/j.jacl.2026.04.018
- 9.Iribarren C, Lu M, Go AS, Rana JS, Ngai K, Rogers AM. Attaining LDL-cholesterol target post major coronary event: Care gap, associated factors and clinical outcomes. American Heart Journal. 2026. https://doi.org/10.1016/j.ahj.2026.107430
- 10.Caklili OT, Haymana C, Demirci İ, Kebapci MN, Sariakcali B, Evren B, et al. Suboptimal LDL‐Cholesterol Control Under the 2019 ESC/EAS Dyslipidemia Guidelines: Results From the Nationwide TEMD‐2 Study in Type 2 Diabetes. Diabetes, Obesity & Metabolism. 2026;28(9):7779-7790. https://doi.org/10.1111/dom.70806
- 11.Guzmán-Aquino SG, Rivera-Sánchez R, Aguayo-Cerón KA, Solis-Navarro M, Calzada-Mendoza CC, Romero-Nava R, et al. Analytical Agreement and Diagnostic Performance of a Commercial Point-of-Care Lipid Testing System for Lipid Profile and Atherogenic Ratios. Diagnostics. 2026;16(19). https://doi.org/10.3390/diagnostics16193116
- 12.Lyman M, Fanshawe JB, Brewin J, Fanshawe TR, Turner PJ, Glogowska M, et al. Introduction of point-of-care blood testing in early intervention in psychosis services: effects on physical health screening. The British Journal of Psychiatry. 2026;228(4):311-316. https://doi.org/10.1192/bjp.2025.28
- 13.Martinez KA, Montori VM, Rodriguez F, Tereshchenko LG, Kovach JD, Boyer C, et al. Association between Exposure to Statin Choice and Adherence to Statins: An Observational Cohort Study. Medical Decision Making. 2025;45(7):884-891. https://doi.org/10.1177/0272989x251346508
- 14.Tichopád A, Donin G, Žigmond J, Ráfl J, Rybář M, Šedová P, et al. Statin adherence improves with age and subsequent treatment sequences: A retrospective cohort study using Proportion of Days Covered (PDC). PLOS ONE. 2025;20(6):e0325293. https://doi.org/10.1371/journal.pone.0325293
- 15.Pivoriunas J, Engebretsen I, Vethe NT, Kristiansen O, Dammen T, Husebye E, et al. Statin adherence in coronary outpatients: The relationship between a novel blood test and pharmacy registry data. Atherosclerosis. 2025;403. https://doi.org/10.1016/j.atherosclerosis.2025.119138
Claim-to-source matrix
What each source supports
Every sourced claim in the new sections maps to the references that support it, the section where it is used, and the limitation a reader should keep in mind. Original executive guidance carries no sources because it is guidance, not a finding.
| Claim group | Sources | Years | Used in | Limitation |
|---|---|---|---|---|
| LDL cholesterol testing and target attainment after major coronary events | [9] | 2026 | Current evidence | Retrospective cohort with median 5.1 years of follow-up; association with outcomes, not causation. |
| LDL target attainment and therapeutic inertia in type 2 diabetes | [10] | 2026 | Current evidence | Cross-sectional study in tertiary endocrine clinics in Turkey. |
| Statin discontinuation and low adherence among people with HIV | [2] | 2026 | Equity and trust | Privately insured adults under 65; claims-based adherence. |
| Statin adherence by age and treatment sequence | [14] | 2025 | Current evidence | Czech claims data; proportion of days covered does not confirm ingestion. |
| Blood test versus pharmacy registry measures of adherence | [15] | 2025 | Current evidence | 451 Norwegian coronary outpatients; single blood sample. |
| Cardiovascular risk scoring at statin initiation, adherence and outcomes | [3] | 2026 | Continuum of care | Historical cohort; risk score is a proxy for shared decision making; residual confounding. |
| Embedded shared decision-making tool and statin prescribing, fills and adherence | [13] | 2025 | Continuum of care | Observational single-system study; adjusted 12-month adherence not significant. |
| Point-of-care lipid testing in psychosis services | [12] | 2026 | Access | Real-world before-after evaluation with regional comparison. |
| Analytical agreement of a point-of-care lipid device | [11] | 2026 | Access | 120 participants; systematic bias versus laboratory methods. |
| Adaptive digital outreach and statin refill | [1] | 2026 | Access | Short-term refill outcomes in one integrated system. |
| Sex differences in LDL control and statin prescribing | [7] [5] | 2026 | Equity and trust | Retrospective chart review and a single-hospital cross-sectional study. |
| Pharmacist-led lipid management | [6] | 2026 | Human infrastructure | Open-label trial of 123 adults in China. |
| Familial hypercholesterolemia case-finding tools in specialty clinics | [4] | 2026 | Human infrastructure | 501 patients in Qatar; clinical criteria without genetic confirmation. |
| LDL calculation method and apparent goal attainment | [8] | 2026 | Human infrastructure | Retrospective data from one hospital information system. |

About the author
Greg Wahlstrom
MBAHCM
President and Chief Executive Officer, The Healthcare Executive
View Greg’s profile©2014 – 2026 The Healthcare Executive. All rights reserved.

